Myopia Market Is Expected To Grow During The Study Period (2019-2032), DelveInsight | Key Companies: Nevakar, Sydnexis, and Several Others

The Myopia Market Size shall grow during the forecast period (2022-2032) owing to the launch of upcoming therapies, the high prevalence of Myopia, advances in pharmacological treatment, personalized treatment approach, advances in models of an alcohol use disorder, and others during the forecast period (2022-2032).

DelveInsight's Myopia Market Insights, Epidemiology, and Market Forecast 2032″ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Myopia Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan).

Key takeaways from the Myopia Market Research Report

• According to a study conducted by Dyanne et al., Myopia occurs in 10% of the general population but is more common in older adults; the prevalence is 20% in those older than 60 years and 50% in those older than 70 years. The increased prevalence in older adults is related to peripheral vascular disease, immunologic disorders, and diabetes mellitus.

• A study by Vitale et al., in the United States, found that the prevalence of moderate Myopia, defined as between -2.00 D and -7.9 D, nearly doubled (from 4% in 1971-1972 to 22.4% in 1999-2004), and that the prevalence of high Myopia, which was defined as more than 8.00 D of Myopia for this study, had increased eightfold during the same period (from 0.2% to 1.6%).

• As per the study by Yotsukura et al., the prevalence of Myopia was 5% among those aged 6-11 years and 94.9% among those aged 12-14 years, and the prevalence of high Myopia was 4.0% among those aged 6-11 years and 11.3% among those aged 12-14 years.

Explore more information of the latest breakthroughs of Myopia Treatment Landscape, click here for Myopia Market Size @ https://www.delveinsight.com/sample-request/myopia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Myopia Overview
Myopia, commonly referred to as shortsightedness, is a common cause of visual disability throughout the world. The prevalence of myopia varies by country and by ethnic group, reaching as high as 70-90% in some Asian populations. Myopia occurs if the eyeball is too long or the cornea (the clear front cover of the eye) is too curved.

Recent Developmental Activities in the Myopia Treatment Landscape

• In November 2020, the company announced that the first patient has completed three year enrollment in the Phase III CHAMP study. The company completed the enrollment of the patients in the Phase III CHAMP study in 2019 and further plans to publish the Phase III clinical study results in 2022, followed by the launch of this therapy in 2023. As per the company, if the phase III gets successful, the company will be eligible to obtain approval from the US Food and Drug Administration (FDA), and hence NVK-002 would represent the first pharmacologic eye drop for this patient population.

• Moreover, in February 2021, Nevakar and Laboratoires Théa entered into an exclusive licensing agreement for the commercialization of NVK-002 in Europe.

• NVK002 is an investigational, preservative-free, low-dose atropine eye drop, using Vyluma's proprietary technology to address stability, tolerability, and safety. The CHAMP (Childhood Atropine for Myopia Progression) study includes children ages three to 17 and administration is a single drop to both eyes, nightly. The CHAMP study is currently testing two concentrations in the United States and Europe. Vyluma has partnered with Laboratories Théa and Zhaoke Ophthalmology for commercialization of NVK002. Théa, the leading independent European pharmaceutical group in ophthalmology, will be responsible for the commercialization of NVK002 in Europe, and for the registration and commercialization in Canada, Mexico, and selected South American countries. Zhaoke Ophthalmology, a leading ophthalmic pharmaceutical company, will be responsible for the clinical development and commercialization of NVK002 in Greater China, South Korea, and certain select countries in Southeast Asia (Brunei, Burma, Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, and Vietnam). It is currently being evaluated in Phase III clinical trial.

• MicroPine is a proprietary microdose formulation of atropine used in our Optejet dispenser and product candidate for the prevention of progressive myopia (nearsightedness) in children. It is believed that Eyenovia's delivery technology is particularly well-suited for this application and patient population, potentially enabling children to easily self-administer atropine medication while minimizing dose-related side effects. Eyenovia is evaluating MicroPine in Phase III program in its CHAPERONE study.

Myopia Epidemiology Segmentation in the 7MM
• Total Myopia Prevalent Cases

• Myopia Age-specific Prevalence

• Myopia Severity-specific Prevalence

• Myopia Diagnosed and Treated Cases

To know more information of the Myopia Epidemiology Segmentation of the report, click here for Myopia Epidemiology Insights @ https://www.delveinsight.com/sample-request/myopia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Myopia Market Insights
The market is segmented by treatment. It has presence of major players in the market such as CooperVision, Johnson & Johnson Vision, Zeiss International, Alcon Vision LLC, and Bausch & Lomb Incorporated, among others across 7MM. The market is consolidated with many available options owing to growing demands. The market is expected to be driven by the factors such as increase in prevalence of myopia, technological development in lenses and surgeries, growing population globally, and surge in adoption rates of minimally invasive surgeries. The market will be hindered because of availability of many options and no permanent cure.

Myopia Emerging Companies and Therapies
• iSee Orthokeratology Contact Lenses (iSee)
• MiSight (CooperVision)
• Paragon CRT® lenses (Paragon Vision)
• NVK-002 (Nevakar)
• Miyosmart (Hoya Vision)
• Sydnexis (SYD-101)

Browse More Related Reports of the Myopia Market Research Reports, click here for Myopia Market Forecast @ https://www.delveinsight.com/sample-request/myopia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Myopia Market Research Report

• Coverage- 7MM

• Myopia Companies- Nevakar, Sydnexis, and others.

• Myopia Pipeline Therapies- NVK-002, SYD-101, and Others

• Myopia Market Dynamics: Myopia Market Drivers and Barriers

Read the Full Research Report of the Myopia Market Forecast Report, click here for Myopia Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/myopia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Myopia Executive Summary
3. Competitive Intelligence Analysis
4. Market Overview at a Glance
5. Disease Background and Overview
6. Patient Journey
7. Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Myopia Market Treatment
11. Marketed Products
12. Emerging Therapies
13. Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Myopia Market Outlook
16. Access and Reimbursement Overview
17. KOL Views
18. Myopia Market Drivers
19. Myopia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Consult with our Business Expert @ Myopia Market Landscape- https://www.delveinsight.com/sample-request/myopia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj

info@delveinsight.com

This release was published on openPR.